JAK2 and essential thrombocythemia: It should be noted the landmark discovery of CALR Exon 9 mutations in 60–80% of JAK2 V617F- and MPL Exon 10-negative ET and PMF cases compels the inclusion of CALR mutation analysis into the molecular diagnostic algorithm for these MPNs21.